ATE254600T1 - Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on - Google Patents

Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on

Info

Publication number
ATE254600T1
ATE254600T1 AT97200175T AT97200175T ATE254600T1 AT E254600 T1 ATE254600 T1 AT E254600T1 AT 97200175 T AT97200175 T AT 97200175T AT 97200175 T AT97200175 T AT 97200175T AT E254600 T1 ATE254600 T1 AT E254600T1
Authority
AT
Austria
Prior art keywords
prodrogen
benzisothiazole
indol
dihydro
chloro
Prior art date
Application number
AT97200175T
Other languages
English (en)
Inventor
John Francis Lambert
Stanley Walter Walinsky
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE254600T1 publication Critical patent/ATE254600T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT97200175T 1996-02-13 1997-01-21 Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on ATE254600T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1156896P 1996-02-13 1996-02-13

Publications (1)

Publication Number Publication Date
ATE254600T1 true ATE254600T1 (de) 2003-12-15

Family

ID=21750970

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97200175T ATE254600T1 (de) 1996-02-13 1997-01-21 Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on

Country Status (10)

Country Link
US (1) US5935960A (de)
EP (1) EP0790236B1 (de)
JP (1) JP2911032B2 (de)
AT (1) ATE254600T1 (de)
CA (1) CA2197272C (de)
DE (1) DE69726206T2 (de)
DK (1) DK0790236T3 (de)
ES (1) ES2210450T3 (de)
MX (1) MX9701116A (de)
PT (1) PT790236E (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT790236E (pt) * 1996-02-13 2004-04-30 Pfizer Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6616270B1 (en) 1998-08-21 2003-09-09 Seiko Epson Corporation Ink jet recording head and ink jet recording apparatus comprising the same
JP2002541098A (ja) * 1999-04-06 2002-12-03 セプラコア インコーポレーテッド ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物
US7030142B1 (en) 1999-04-06 2006-04-18 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
CN100340557C (zh) * 2002-10-24 2007-10-03 辉瑞产品公司 具有神经镇静活性的齐拉西酮的酰基衍生物
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
PL391810A1 (pl) 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
HUT61760A (en) * 1988-09-16 1993-03-01 Pfizer Process for producing bridged, bicyclic imides comprising 4-/4-(3-benzisothiazolyl)-1-piperazinyl/-butyl group and pharmaceutical compositions comprising such compounds
US5087627A (en) * 1989-03-15 1992-02-11 Santen Pharmaceutical Co., Ltd. Agent for treatment of disorders of the cerebro-neural transmission system
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT790236E (pt) * 1996-02-13 2004-04-30 Pfizer Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona

Also Published As

Publication number Publication date
DE69726206T2 (de) 2004-04-15
DE69726206D1 (de) 2003-12-24
MX9701116A (es) 1998-04-30
EP0790236B1 (de) 2003-11-19
EP0790236A1 (de) 1997-08-20
JP2911032B2 (ja) 1999-06-23
JPH09227516A (ja) 1997-09-02
ES2210450T3 (es) 2004-07-01
CA2197272A1 (en) 1997-08-14
US5935960A (en) 1999-08-10
CA2197272C (en) 2001-01-23
PT790236E (pt) 2004-04-30
DK0790236T3 (da) 2004-02-23

Similar Documents

Publication Publication Date Title
NO933093L (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2H-indol-2-on hydroklorid
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
YU17397A (sh) Mezilat trihidrat 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)1etil)-6-hloro-1,3-dihidro-2h-indol-2-ona
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
DE60110262D1 (de) Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren
NO924696D0 (no) Fremgangsmaate for fremstilling av oksazolidinon- og tiazolidinon-derivater
ATE254600T1 (de) Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
CY1107300T1 (el) Ακυλικα παραγωγα της 5-(2-(4-(1,2-βενζισοθειαζολ-3-υλο)-1-πιπεραζινυλ)αιθυλο)-6-χλωρο-1,3-διυδρο-2h-ινδολ-2-ονης με νευροληπτικη δραστικοτητα
ATE337313T1 (de) 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
DE60115062D1 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
MY109504A (en) Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2- one hydrochloride
ECSP972089A (es) Sal mesilato trihidrato de 5-[2-[4(1,2-benzoisotiazol-3-il]-1-piperazinil)etil]-6-cloro- 1,3- dihidro- 2h- inddol - 2 - ona
HUP9902404A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(2H)-indol-2-on (ziprazidon) mezilát-dihidrát sói, a vegyületek előállitása és dopamin D2 antagonistaként történő alkalmazása

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0790236

Country of ref document: EP

REN Ceased due to non-payment of the annual fee